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Background: Plant and marine n-3 fatty acids (FA) may favorably modify select markers of cardiovascular disease
risk. Whether supplementing the habitual diet of lacto-ovo-vegetarians (LOV) with walnuts (containing α-linolenic
acid, ALA) and n-3 FA enriched eggs (containing primarily docosahexaenoic acid, DHA and ALA) would have
equivalent effects on CVD risk factors is explored in this study.
Methods: In this study, 20 healthy free-living LOVs following their habitual diet were randomly assigned in a
crossover design to receive one of three supplements: n-3 FA enriched egg (6/week), walnuts (28.4 g, 6/week) or a
standard egg, 6/week (control) for 8 weeks each with 4-wk washout between treatments. Erythrocyte membrane
fatty acids, serum lipids and inflammatory markers were measured at the end of each treatment.
Results: Dietary compliance was observed by an expected increase in erythrocyte membrane ALA following the
walnut treatment and in DHA following the n-3 FA enriched egg treatment. Walnut treatment lowered serum
triacylglycerol, total cholesterol and Apo B (p < 0.05) compared to the standard egg but not the n-3 FA enriched
egg treatment. However, walnut treatment significantly reduced total: HDL cholesterol ratio compared to both egg
treatments. There were no differences between treatments for any of the inflammatory markers.
Conclusions: For LOV, a direct source of DHA such as n-3 FA enriched eggs seems necessary to increase membrane
levels of DHA. However for producing an overall favorable blood lipid profile, daily consumption of a handful of
walnuts rich in ALA may be a preferred option for lacto-ovo vegetarian.
Keywords: Walnuts, n-3 fatty acid enriched eggs, Lacto-ovo vegetarians, Cardiovascular risk factors, Eggs,
Inflammation markers, Blood lipidsBackground
The major plant n-3 fatty acid α-linolenic acid (ALA) is
found in walnuts, soybean, canola oil, and flaxseed; while
the major marine n-3 fatty acids, eicosapentaenoic (EPA)
and docosahexaenoic acids (DHA), are found in cold-
water fatty fish and flax or soy-fed poultry and farm ani-
mals [1,2]. Diets containing high amounts of both plant* Correspondence: srajaram@llu.edu
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article, unless otherwise stated.and marine derived n-3 fatty acids are associated with re-
duced risk of cardiovascular disease (CVD) [3,4], but stud-
ies indicate Americans do not consume enough n-3 fatty
acids [1,5,6]. The cardio-protective effects of n-3 fatty
acids may be partially mediated via favorable changes in
blood lipids and inflammation [7,8]. Whether or not ALA
and EPA/DHA have equivalent effects on CVD risk fac-
tors specifically in healthy lacto-ovo-vegetarians (LOV)
has not extensively studied.
Some fortified dairy products and eggs contain very
small amounts of DHA (0.02-0.3 g/serving) and are thed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Burns-Whitmore et al. Nutrition Journal 2014, 13:29 Page 2 of 9
http://www.nutritionj.com/content/13/1/29only direct sources of DHA in the LOV diet [1,6]. The
only vegan DHA option is an algae-based supplement
[9]. Vegans and LOVs depend on the endogenous pro-
duction of EPA and DHA from ALA; however, this en-
dogenous conversion is inefficient with only 5-7% of
dietary ALA converting to EPA and DHA [10]. The diet-
ary ratio of n-6 to n-3 fatty acids influences conversion
of ALA to EPA and DHA [6]. While LOVs and vegans
do consume significant amount of ALA in their diet,
overall their linoleic acid (LA) intake is many folds
higher than ALA intake producing high n-6: n-3 fatty
acid ratio. This may suppress the conversion of ALA to
EPA and DHA (1, 6).
Consumption of 57-71 g/day of ALA rich walnuts
decreases total and LDL cholesterol (LDL-C) and triac-
ylglycerol (TAG) in normo- and hypercholesterolemic
individuals, resulting in a favorable reduction in CVD
risk (11-16). Studies with cold-water fatty fish demon-
strate reduction of atherosclerotic plaque formation,
lowering of TAG and an increase in HDL-C, support-
ing the rationale for including fatty fish in the diet to
prevent Coronary Heart Disease [3,11-13]. We recently
examined the effects of consuming fatty fish and wal-
nuts on serum lipids and found that walnuts lowered
total and LDL-C while the fatty fish decreased serum
TAG and increased HDL-C [14]. Since LOVs do not
consume fish, an alternate source of long chain n-3 fatty
acids for LOVs could be n-3 fatty acid enriched eggs.
Chickens fed flaxseed, soy, or algal marine sources, in-
corporate DHA and ALA into their eggs, which results in
the production of n-3 fatty acid enriched eggs [15,16].
N-3 fatty acid enriched eggs fed to hypercholesterol-
emic non-vegetarians showed increase in HDL-C, de-
crease in platelet aggregation, and significant lowering of
TAG [17-20]. Some studies have looked at the effect of
feeding n-3 fatty acid enriched eggs on blood lipids, but
none have compared the effects of ALA-rich walnuts
with that of n-3 fatty acid (primarily DHA) enriched egg
on CVD risk factors especially among LOVs.
Methods
Participants
Healthy LOV subjects were recruited from southern
California via a multistage screening process with com-
munity advertisements through local newspapers and
flyers. Potential candidates that responded were pre-
sented with the study information at group meetings
and were asked to sign the informed consent if they de-
cided to proceed with the study. Screening process also
included interviews with two investigators to assess po-
tential compliance. Men and women between the ages of
21-90 years and who had normal total cholesterol
(Total-C) and TAG levels were included in the study.
Participants were excluded if they had existing medicalconditions, were <21 or ≥ 90 years of age, were smokers,
drank alcohol, took supplements, not willing to follow
dietary intervention and instructions, were on choles-
terol lowering medications, or on daily prescription anti-
inflammatory medication, and were LOV for < 3 months.
The minimum sample size required for a crossover de-
sign to detect a mean absolute difference in serum
LDL-C of 0.26 mmol/L at α =0.05 and power > 80% was
calculated to be 18. Assuming a dropout rate of 20%,
we recruited 26 subjects for this study. All participants
signed a written informed consent approved by the
Internal Review Boards at Loma Linda University,
Loma Linda, CA and California State Polytechnic Uni-
versity, Pomona, CA.
Study design and protocol
The study was a randomized, crossover (3 × 3 Latin-
square), free-living intervention study in which subjects
were blinded to the egg treatments. Participants were
asked to follow their habitual diet and add the treatment
food as a supplement. They were randomly assigned to
n-3 fatty acid enriched egg (6/wk), walnuts (28.4 g, 6x/wk)
or standard egg, 6/wk (control). Treatments were followed
for 8 weeks each in a crossover design, with a 4-week
washout period between treatments. Previous studies
[14,21,22] have shown that 3-6 weeks intervention and
4 weeks washout is adequate to see changes especially for
serum lipids and red cell membrane fatty acids.
The n-3 fatty acid enriched eggs were obtained from
chickens fed an organic, vegetarian diet containing flax-
seed and the standard eggs for the control treatment
were obtained from chickens fed organic, vegetarian diet.
The n-3 fatty acid composition of the two eggs was pre-
viously published [23]. The n-3 fatty acid enriched egg
contained ~500 mg DHA, 40 mg EPA and 1 g ALA per
egg yolk while the standard egg yolk contained 110 mg
DHA, negligible amount of EPA and 0.15 g ALA. The
walnuts used in the study provided 2.95 g ALA and 10.4
LA per 28.4 grams or 1 ounce of walnuts (Covance,
Madison, WI).
Participants received diet counseling and their inter-
vention foods from a Registered Dietitian (RD) every
two weeks during the treatment periods. Participants
were asked to avoid excess amounts of foods rich in n-3
fatty acids such as flax, soy, or canola oil, and to refrain
from consuming any additional eggs or walnuts other
than the ones supplied during the study. The instruc-
tions provided to the subjects were to add the treatment
food to their habitual diet. They could incorporate the
foods in any form they desired. Eggs could be cooked as
omelet or hard boiled eggs or incorporated into a dish
provided the participant consumed the entire serving.
Walnuts could be eaten raw or used on salads, muffins,
etc. Diet and caloric consumption was determined by
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there were no instructions provided regarding caloric in-
take. Subjects were asked to maintain the same lifestyle
habits with which they entered the study such as the
level and type of physical activity.
Quality control
Quality control and compliance was ensured among study
participants by: 1) counseling with the RD throughout the
study; 2) maintaining a daily diary to record deviations in
food and medicine intake; 3) obtaining three 24-hour re-
calls during each treatment period to assess nutrient in-
take (Nutrition Data System-Research software -NDS-R,
Nutrition Coordinating Center, Division of Epidemiology
© 2007 by the Regents of the University of Minnesota);
4) assessing fatty acid composition of erythrocyte mem-
branes at the end of each treatment period to assess
compliance to treatment food (Lipomics Technologies,
West Sacramento, CA).
Data collection
Participant’s body weight was assessed at baseline and
end of all treatments (Tanita TBF 310-GS scale, Tanita
Corporation of America Inc., Arlington Heights, IL,
USA). Twelve-hour fasting blood samples were collected
at baseline and end of each treatment period. Serum was
separated by centrifugation, aliquoted and stored at -80°C
until further analyses. The erythrocytes were washed and
stored in saline at –80°C until further analyses.
Analyses of serum markers
Lipomics Technologies (West Sacramento, CA) ex-
tracted and analyzed the erythrocyte membrane lipids as
described previously [24]. The Nutritional Assessment
Core at the University of California, Davis (supported by
NIH NIDDK grant 35747), performed the serum lipid and
lipoprotein analyses [14,24]. Serum interleukin 1β (IL-1β),
interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α),
soluble intracellular adhesion molecule-1 (sICAM-1), and
sE-Selectin were analyzed utilizing the quantitative high
sensitivity technique according to the supplier’s instruc-
tions (R&D Systems, Minneapolis, MN). High-sensitivity
C-reactive protein (Hs-CRP) was analyzed using Enzyme-
linked immunosorbent assay (Diagnostic Systems Labora-
tories, Inc., Webster, TX).
Statistical analysis
Analysis was carried out using the SAS Mixed Procedure
(SAS/STAT software, Version 9.2 of the SAS/SAT
System for Unix, 2008. SAS Institute Inc., Cary, NC),
which correctly analyzes data with heterogeneous vari-
ances. A heterogeneity model was used for arachidonic
acid and total n-3 fatty acids, and homogeneity model
was used for all other nutrients. When ANOVA wassignificant (P < 0.05), paired comparison tests among
the treatments were carried out, and adjusted for mul-
tiple comparisons by using the Tukey-Cramer method.
Results are presented as least-squares means and 95%
CIs after back-transformation.
Erythrocyte membrane fatty acids, blood lipids and
inflammatory factors data were analyzed by using
mixed linear models that included fixed terms for treat-
ment and period, and a random term for subjects.
TAG, HDL-C and all inflammatory factors except
sICAM, were normalized by log-transformation. Results
for these outcomes were transformed back into their
original units, and are presented as least-squares geo-
metric means and their 95% C.I. Results with a P value
of <0.05 were considered statistically significant.
Dietary EPA and DHA, which contained many zero-
valued observations, could not be normalized by trans-
formation. Therefore, tests for significant differences
among treatments were carried out by using two-way,
fixed-effects ANOVA on the ranks of the subject means.
When ANOVA was significant, paired comparison tests
were used, and adjusted for multiple comparisons.
Baseline values for the variables are not shown in ta-
bles as this is a crossover study design where the com-
parison between each treatment is more relevant than
comparison to baseline; however, the baseline-adjusted
analyses was carried out utilizing fixed covariates repre-
senting the period baseline and the subject-average
period baselines were added to the mixed-effects model
for serum lipids, inflammatory markers and erythrocyte
membrane fatty acid analysis.
Results and discussion
Subjects
Six participants withdrew from the study because of
family or job pressures or allergies unrelated to treat-
ment foods. Twenty participants completed the study.
The average subject age was 38 ± 3 years (range 21-
64 years) and BMI was 23 ±1. There were 16 females
and 4 males representing several ethnic groups: White
(n = 10), Latino (n = 5), Asian (n = 2), and other (n = 3).
Dietary intake and compliance
The dietary intakes from the 24-hour recalls for energy,
carbohydrate, fiber, total fat, saturated fat, and monoun-
saturated fat were not significantly different between the
three treatments (Table 1). As expected, walnut group
had higher intake of total polyunsaturated fat (PUFA),
total n-6 and n-3 PUFA, LA, ALA compared to the egg
treatment groups since walnut treatment group had 1.5
times higher LA and 3 times higher ALA from diet than
the egg treatment groups.
Similarly egg treatment groups had higher protein,
arachidonic acid and cholesterol than walnut treatment
Table 1 Diet composition from the 24-hour recalls*
DIET TREATMENTS









P-value3(95% CIs2) (95% CIs2) (95% CIs2)
Kcal
1902 – 1895 – 1729 – 0.159
(1766, 2049) (1744, 2060) (1597, 1872)
KJ
7963 – 7934 – 7239 – 0.159
(7394, 8579) (7302, 8625) (6686, 7838)
Protein (g)
69a 14.51 59a 12.45 54b 12.49 <0.013
(62, 76) (53, 67) (48, 61)
Carbohydrate (g)
281 50.10 278 58.68 248 57.37 0.172
(255, 309) (250, 309) (224, 275)
Total fat (g)
58 27.4 58 27.6 64 33.3 0.537
(50, 67) (50, 68) (55, 75)
Saturated (g)
16.3 7.71 15.9 7.55 15.1 7.86 0.8138
(13.7, 19.4) (13.1, 19.4) (12.5, 18.1)
MUFA (g)
21.9 10.4 21.8 10.4 20.1 10.5 0.7558
(18.4, 26.1) (17.9, 26.4) (16.6, 24.2)
PUFA (g)
13.8a 6.53 14.7a 6.98 22.5b 11.7 <0.0001
(11.8, 16.1) (12.3, 17.5) (19.0, 26.6)
Total n-6 (g)
11.0a 5.21 12.3a 5.84 18.9b 9.84 <0.0001
(9.4, 12.9) (10.3, 14.6) (16.0, 22.3)
Linoleic (g)
10.9a 5.16 12.2a 5.79 18.9b 9.84 <0.0001
(9.3, 12.7) (10.3, 14.5) (16.0, 22.3)
Arachidonic (g)
1.14a 0.54 1.05b 0.50 1.01c 0.53 <0.0001
(1.09, 1.18) (1.04, 1.07) (1.00, 1.02)
Total n-3 (g)
1.16a 0.55 1.38a 0.66 3.10b 1.61 <0.0001
(0.93, 1.44) (1.08, 1.75) (2.65, 3.63)
α-Linolenic (g)
1.04a 0.49 1.35a 0.64 3.07b 1.61 <0.0001
(0.86, 1.26) (1.09, 1.67) (2.50, 3.76)
EPA (g)
0.128a 0.06 0.003b 0.00 0.001b 0.00 <0.0001
(0, 0.676) (0, 0.020) (0, 0.015)
DHA (g)
0.126a 0.06 0.021b 0.00 0.002c 0.00 <0.0001
(0, 0.378) (0, 0.080) (0, 0.015)
Cholesterol (mg)
214a – 136a – 46b – <0.0002
(131, 351) (78, 236) (27, 77)
Fiber (g)
25 – 28 – 25 – 0.458
(22, 29) (24, 32) (21, 28)
*Means of three 24-hour diet recalls.
1Least squares means (LS Means), after back transformation, from 2-way ANOVA with fixed effects for treatment and subject performed on log-transformed data.
For EPA and DHA, the recalls for each subject were averaged, and the mean of these subject means is presented. Values in the same row with different superscript
letters are significantly different p < 0.05.
2Ranges, instead of 95% CIs, are given for EPA and DHA.
3P-values respectively for N-3 fatty acid enriched egg and standard egg, N-3 fatty acid enriched egg vs. walnut, and standard egg vs. walnut, adjusted for multiple
comparisons by the Tukey-Cramer method; except for EPA and DHA which were adjusted by using the Conover method.
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group had higher EPA and DHA than the other two
treatment groups and the standard egg treatment hadhigher DHA than the walnut treatment group which
more or less reflects the fatty acid composition of the
treatment food. The higher ALA in standard egg group
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significant could reflect other sources of ALA in the diet
and not the treatment per se.
Mixed linear model analyses for changes in subject
body weight and body composition were not significant
(data not shown), indicating that participants maintained
energy balance even after adding a treatment food to
their habitual diets. The body composition data estab-
lished confidence in the 24-hour recall information since
calorie intake and weight change was not significantly
different during each treatment.
Incorporation of fatty acids into the erythrocyte mem-
brane is presented in Table 2. As expected, LA and ALA
were significantly higher during the walnut compared to
the egg treatments. DHA was higher during the n-3 fatty
acid enriched egg compared to the standard egg and
walnut treatment periods. EPA was not significantly dif-
ferent between treatments. There was also a slightTable 2 Fatty acid composition of erythrocyte membranes be
DIET TREAT
Fatty acid1 Standard egg (control) N-3 fatty ac
μg/mole% Baseline End2 Baseline
Saturated
41.1 41.0 40.9
(40.7, 41.5) (40.2, 41.9) (40.5, 41.3)
Trans4
0.05 0.02 0 .06
(0.04, 0.06) (0.01, 0.03) (0.04, 0.08)
Monounsaturated
15.1 15.3 15.4
(14.8, 15.4) (14.8, 15.7)a (15.2, 15.7)
Polyunsaturated
36.3 35.6 35.6
(35.9, 36.7) (34.8, 36.4) (35.3, 35.9)
n-6 (total)
30.4 29.7 29.8
(30.1, 30.7) (29.1, 30.4) (29.4, 30.2)
Linoleic
11.5 10.9 11.3
(11.3, 11.7) (10.5, 11.3)a (11.0, 11.6)
Arachidonic
13.6 13.4 13.2
(13.3, 13.9) (13.0, 13.7) (12.9, 13.5)
n-3 (total)
5.7 5.68 5.6
(5.5, 5.9) (5.48, 5.88) (5.4, 5.8)
α-Linolenic
0 .14 0.14 0.13
(0.13, 0.15) (0.12, 0.16)a (0.12, 0.14)
EPA5
0.28 0.34 0.31
(0.25, 0.31) (0.31, 0.38) (0.29, 0.33)
DHA5
2.79 2.90 2.72
(2.64, 2.94) (2.74, 3.05)b (2.57, 2.87)
1N = 18. Fatty acid values are presented in least square means with 95% confidence
different, P < 0.05.
2End values are baseline-adjusted according to the method of Kenward and Roger.
3Mixed effects model, controlling for treatment and period effect, adjusted for mult
4Analysis was performed after log-transformation. Results were transformed back in
5EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid.decrease in monounsaturated fat in the walnut diet com-
pared to the egg treatments.
Serum cardiovascular disease risk markers
The serum lipid and lipoprotein values following the
three treatments are presented in Table 3. On the walnut
treatment there was a significant decrease in total chol-
esterol, triglyceride and apo B, compared to the standard
egg but not the n-3 fatty acid enriched egg treatment.
However the total-C: HDL-C ratio was lower in the wal-
nut treatment compared to both the egg treatments.
There were no significant differences (p > 0.05) among
treatments in any of the inflammatory markers assessed
in this study (Table 4).
There is substantial evidence that eating fatty fish at
least twice a week offers cardiovascular protection [1-3].
However, for vegetarians and for those that do not in-
clude fish in their diet for a variety of reasons, otherfore and after each of the three dietary treatments
MENTS
id enriched egg Walnut Global
P value3End2 Baseline End2
40.9 41.4 41.2 0.9579
(39.7, 42.1) (40.8, 42.0) (40.0, 42.3)
0.03 0 .06 0.03 0.5076
(0.02, 0.06) (0.05, 0.07) (0.02, 0.05)
15.4 14.9 14.4 <0.0003
(15.0, 15.9)a (15.2, 14.6) (13.9, 14.8)b
35.8 36.1 36.0 0.1761
(35.0, 36.7) (34.5, 36.5) (35.8, 37.4)
29.7 30.0 30.5 0.2880
(28.7, 30.6) (29. 6, 30.4) (29.6, 31.5)
10.8 11.4 11.9 <0.0001
(10.4, 11.3)a (11.1, 11.7) (11.5, 12.3)b
13.6 13.3 13.4 0.7111
(13.2, 13.9) (13.02, 13.6) (13.0, 13.7)
5.97 6.0 5.79 0.0903
(5.76, 6.17) (5.76, 6.24) (5.59, 5.98)
0.15 0.18 0.19 <0.0000
(0.13, 0.16)a (0.17, 0.19) (0.18, 0.20)b
0.30 0.30 0.31 0.1824
(0.26, 0.33) (0.27, 0.33) (0.27, 0.34)
3.15 3.12 2.71 <0.0015
(3.00, 3.32)a (2.90, 3.34) (2.55, 2.87)b
intervals. Values within a row with different superscript letters are significantly
iple comparisons using Tukey-Kramer.
to original units and are presented as geometric mean and CI.
Table 3 Serum lipids and lipoproteins before and after each of the three dietary treatments
DIET TREATMENTS
Standard egg (control) n-3 FA enriched egg Walnut Global
P Value3Lipid variable1 Baseline End2 Baseline End Baseline End
Cholesterol(s)
Total (mmol/L)
4.79 5.09 4.62 4.96 4.79 4.77
<0.0348
(4.67, 4.91) (4.92, 5.26)a (4.50, 4.74) (4.79, 5.12)ab (4.67, 4.92) (4.60, 4.94)b
HDL4 (mmol/L)
1.29 1.33 1.27 1.30 1.28 1.31
0.7736
(1.17, 1.41) (1.25, 1.41) (1.15, 1.40) (1.23, 1.38) (1.15, 1.40) (1.23, 1.39)
LDL (mmol/L)
2.75 3.03 2.63 2.96 2.81 2.86
0.2866
(2.63, 2.87) (2.87, 3.19) (2.50, 2.75) (2.80, 3.12) (2.69, 2.94) (2.70, 3.02)
LDL:HDL
2.13 2.31 2.06 2.32 2.20 2.19
0.1432
(2.03, 2.25) (2.19, 2.43) (1.97, 2.18) (2.20, 2.44) (2.00, 2.40) (2.07, 2.31)
Total cholesterol:HDL
3.71 3.86 3.63 3.84 3.76 3.64
<0.0136
(3.48, 4.00) (3.72, 4.00)a (3.40, 3.91) (3.70, 3.98)a (3.51, 4.05) (3.50, 3.79)b
Triacylglycerides4 (mmol/L)
1.15 1.12 1.13 0.97 1.13 0.92
<0.0434
(1.10, 1.21) (1.00, 1.26)a (1.07, 1.18) (0.87, 1.08)ab (1.07, 1.18) (0.83, 1.03)b
Apolipoprotein A (g/L)
1.54 1.62 1.56 1.59 1.57 1.59
0.6416
(1.49, 1.59) (1.57, 1.67) (1.51, 1.61) (1.53, 1.64) (1.53, 1.62) (1.54, 1.64)
Apolipoprotein B (g/L)
0.84 0.94 0.82 0.89 0.89 0.86
<0.0211
(0.77, 0.91) (0.90, 0.98)a (0.77, 0.87) (0.85, 0.93)ab (0.82, 0.96) (0.82, 0.90)b
Triacylglycerides: Apo B4
1.37 1.10 1.38 1.02 1.27 1.01
0.4541
(1.33, 1.43) (0.99, 1.22) (1.36, 1.39) (0.91, 1.13) (1.23, 1.31) (0.91, 1.12)
Apo B: Apo A
0.55 0.59 0.52 0.56 0.57 0.54
0.0527
(0.52, 0.57) (0.56, 0.62) (0.51, 0.54) (0.54, 0.59) (0.54, 0.59) (0.51, 0.57)
1Values within a row with different superscript letters are significantly different, P < 0.05. All results are presented as geometric mean and 95% CI.
2End values are baseline- adjusted according to the method of Kenward and Roger.
3Mixed effects model, controlling for treatment and period effect, adjusted for multiple comparisons using Tukey-Kramer.
4Analysis performed after log-transformation. Results have been transformed back into original units and presented as geometric mean and 95% CI.
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DHA are n-3 fatty acid enriched eggs and foods fortified
or enriched with n-3 fatty acids [1,6]. For vegans it is
even more difficult to rely on diet alone to obtain long
chain n-3 fatty acids and they may have to resort to sup-
plements made from microalgae oils [9]. Although theTable 4 Serum inflammatory markers after each of the three
DIET TREAT
Inflammatory marker Standard egg (control) n-3 F
TNF-α2 (pg/mL) 0.33 (0.15, 0.72) 0.3
E-selectin2 (ng/mL) 0.79 (0.55, 1.12) 0.7
IL-12 (pg/mL) 3.10 (2.52, 3.82) 3.1
IL-62 (pg/mL) 0.89 (0.66, 1.19) 0.9
sICAM3 (ng/mL) 9.13 (8.20, 10.06) 9.4
hs-CRP3 (ng/mL) 1.95 (1.39, 2.51) 2.6
1Global P-value for significant difference among treatments.
2P-values were determined by using mixed linear models, adjusting for subject and
95% CIs after back-transformation.
3P-values determined by using Friedman’s chi-squared test.: TNF-α-Tumor necrosis f
hs-CRP-High sensitivity c-reactive protein.body can convert the plant n-3 fatty acid ALA into EPA,
the conversion to DHA seems to be less efficient [10]. In
this study we compared ALA rich walnuts and n-3 fatty
acid enriched (primarily DHA) eggs with a standard egg
control with respect to their effects on select CVD risk
factors among lacto-ovo-vegetarians (LOV). Adding ~24 g/ddietary treatments
MENTS
A enriched egg Walnut Global P-value1
0 (0.14, 0.65) 0.32 (0.15, 0.69) 0.30
2 (0.51, 1.02) 0.77 (0.55, 1.10) 0.43
9 (2.60. 3.92) 2.99 (2.43, 3.67) 0.71
7 (0.72, 1.29) 0.79 (0.59, 1.06) 0.23
2 (8.79, 10.05) 9.78 (8.84, 10.73) 0.81
4 (1.33, 3.96) 2.36 (1.31, 3.42) 0.75
period effects, on log-transformed data. Results are least square means and
actor-α; IL-Interleukin; sICAM-Soluble intracellular adhesion molecule;
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lowered total-C and TAG compared to eating 6 stand-
ard eggs a week. More importantly, adding ALA rich
walnuts to the habitual diet of LOV lowered the ratio of
total: HDL cholesterol compared to both egg treat-
ments, even when the egg contained a significant
amount of DHA.
Previous studies have shown that feeding 42-57 grams
of walnuts per day (1.5-2 ounces/d) lowers total-C, LDL-
C and TAG in both normal and hypercholesterolemic
individuals [21,22,25-28]. While we showed a significant
lowering in total-C and TAG, LDL-C remained un-
changed. This could either be due to lower baseline
LDL-C levels in our normocholesterolemic subjects or
because of the low dose of walnuts (‵24 g/d) used in our
study compared to higher amounts typically used in
other feeding studies [14,21,22,25-27]. The lowering of
serum total cholesterol by walnuts is consistent with
previous findings (13, 20). While it seems that this is
due to a lower intake of cholesterol in the walnut treat-
ment compared to the egg treatments, it is known that
dietary fatty acids are better predictors of serum choles-
terol than dietary cholesterol per se. In fact we have ob-
served decreases in serum cholesterol following walnut
enriched diet even when dietary cholesterol intake was
similar to the control diet (20).
In previous studies it has been observed that DHA in-
creases LDL-C [14,29]. It was interesting however; that
the n-3 fatty acid enriched egg treatment resulted in
cholesterol levels lower than the standard egg treatment
although the values were not significant statistically.
This may be attributed to the higher ALA content (1 g/
egg yolk) of the n-3 fatty acid enriched eggs (almost half
of what was found in the one ounce of walnuts) which
were derived from flaxseed meal fed chicken compared
to only 0.1 g ALA per standard egg yolk.
In a previous study comparing fatty fish and walnuts,
we showed that walnuts lowered total and LDL-C, while
the fatty fish lowered TAG and increased HDL-C com-
pared to the other treatment [14]. In the present study,
TAG decreased 13% (not statistically significant) on the
n-3 fatty acid enriched egg treatment and 18% on the
walnut treatment compared to the standard egg treat-
ment. 13-18% decrease is clinically relevant and suggests
that ALA and EPA/DHA can both lower triglyceride
levels. In our previous study with fatty fish and walnuts
we showed a two fold increase in erythrocyte EPA levels
following fatty fish intake compared to walnuts and a
corresponding lowering of TAG only in the fatty fish
diet group [14]. In this study the EPA in erythrocyte
membrane were not different among treatments but
DHA was significantly higher in the n-3 fatty acid
enriched egg treatment compared to the other two treat-
ments. These observations do not help explain thegreater TAG lowering seen with walnut treatment. How-
ever, the total n-3 fatty acids derived from the diet was 3
times higher in the walnut treatment compared to the
egg treatments. Perhaps this may explain why walnuts
produced a more significant effect on TAG than the n-3
fatty acid enriched eggs.
The total: HDL cholesterol ratio is considered a clin-
ical benchmark to assess risk of CVD [30]. Walnut treat-
ment was most effective in reducing this ratio compared
to both the egg treatments. Along with this ratio, the
Apo B: Apo A-1 ratio also approached significant differ-
ence between treatments with a lower ratio after the
walnut treatment compared to the standard egg treat-
ment. This suggests that overall a more favorable lipid
profile was achieved through eating 1 ounce of walnuts
6 times a week compared to eating 6 standard eggs.
These effects of walnuts may be mediated partly by
the fatty acid composition of walnuts but may extend
beyond the lipid matrix of the walnut. The EPA levels in
erythrocyte membrane are similar in all three treat-
ments. Although EPA levels in the walnut treatment
group did not increase as expected, this might be due to
the high n-6 fatty acid intake. On the other hand the
DHA level in erythrocyte membrane in the walnut treat-
ment was significantly lower than the n-3 FA enriched
egg treatment. This suggests that consumption of ALA
rich foods alone may not be sufficient to achieve DHA
status in LOVs when compared to LOVs that consume a
direct source of DHA. Future research looking at a
higher dose of walnuts or other ALA rich foods, or a
diet treatment longer than 8 weeks may be required to
determine if erythrocyte incorporation of DHA increases
under these conditions. However for the cardiovascular
risk markers measured, the levels of DHA in erythrocyte
membrane does not seems to be a limiting factor, at
least in this study.
Inflammation plays a role in the development and pro-
gression of atherosclerosis and contributes to an in-
creased risk of CVD [7]. There is some evidence to
suggest that n-3 fatty acids may lower inflammation
[7,8,22], as indicated by serum markers of inflammation,
but these finding are not consistent [31,32]. In our study
we did not show any significant changes in inflammatory
markers following either walnut or n-3 fatty acid
enriched egg treatments. Most of the studies that have
looked at healthy individuals and found no effect of n-3
fatty acids on inflammatory biomarkers especially the cy-
tokines [31]. However, the soluble adhesion molecules
sICAM-1 and sVCAM-1 were decreased following in-
take of n-3 fatty acids in healthy subjects but only at
high dose (~2 g/d of EPA and DHA) or with longer dur-
ation of intervention (12 weeks) [32]. Subjects in our study
on the n-3 fatty acid enriched eggs obtained ~500 mg
DHA per egg yolk but very little EPA (~30 mg/egg yolk)
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nuts on the adhesion molecule sE-selectin has been ob-
served, but only when walnuts and other ALA rich
foods contributed at least 6.5-12% of the total energy of
the diet [33-35]. Reducing levels of cellular adhesion
molecules will have a significant role in modulating the
atherosclerotic process and therefore, future studies
considering dietary modification with n-3 fatty acids
must be mindful of appropriate dose and duration espe-
cially, among healthy individuals.
Previously we observed that plasma levels of eicosa-
noids such as prostaglandin (PGE2) and thromboxane
(TXA2) metabolites were lowered following the intake of
two fatty fish meals (EPA + DHA of 780 mg/d) per week
[34]. It is known that the eicosanoids produced from
EPA is anti-inflammatory and those derived from arachi-
donic acid pro-inflammatory [36]. The effect that we ob-
served was also seen with walnut intake (42.5 g/d) in
that same study, which is attributed to not just the ALA
content but also to the γ-tocopherol content of walnuts,
known to inhibit the activity of cyclooxygenase enzyme
[37]. Since we did not measure these biomarkers in the
present study, whether or not these markers would have
been influenced following the consumption of low dose
walnuts or n-3 fatty acid enriched eggs remains unresolved.
This was a free-living study with the rigor of control
not nearly the same as in metabolically controlled stud-
ies. On the other hand, free living conditions in which
subjects follow their habitual diet with very little dietary
modification provides more generalizable results since it
reflects more realistically what the general population
would eat. Since this study was done in healthy LOVs
who limit the amount of animal products in their diet,
caution must be used in interpretation of the results for
people with chronic diseases, people that consume other
animal products and people that may exhibit sensitivity
to dietary cholesterol.
Conclusion
Our study suggests that for lacto-ovo-vegetarians, re-
placing standard eggs with n-3 fatty acid enriched eggs
in their diet may be an option to increase DHA content
of erythrocyte membranes. However, to influence blood
lipid risk factors, it seems that eating a handful of wal-
nuts daily may have overall better benefits for lacto-
ovo-vegetarians.
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